Assessment of Pharyngeal Carriage of Microorganisms Responsible for

Status Completed

Clinical Trial Summary

The objective of this project is to study the prevalence of viruses and bacteria responsible for transmissible acute respiratory infections in the respiratory tract of pilgrims returning from the trip. The patients included, will be the consultant pilgrims to the traveler health center, and before leaving for Hajj. Based on the results obtained in previous studies, it is estimated that 200 pilgrims will be included each year, 600 in total (inclusion period of 3 years). Respiratory secretions are then collected by nasal swab and throat (swab) prior to departure for the hajj. In return, patients will be reconvened systematic consultation to record medical events potentially encountered during the trip, and it will again be performed the same nasal swabs and throat. It will then be performed on these samples' return from hajj "molecular detection (PCR and RT-PCR) of 35 viruses and bacteria respiratory tropism: influenza (3), RSV (2), metapneumovirus (1), Coronavirus (4), Parainfluenzavirus (4), enteroviruses (4), rhinovirus (1), adenovirus (6) bocavirus, polyomavirus (2), pneumococcus, Bordetella pertussis, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Coxiella burnetii. Samples "return of hajj" positive should be cultured for the isolation of the strain. For patients positive return, it will be done further research of these 35 viruses and bacteria on samples "start of hajj," the same method described above. In addition to this systematic consultation, and if symptoms return, the pilgrims will be seen in consultation for a diagnosis evaluation and therapeutic management. This study will shed light on the acquisition of microorganisms respiratory tropism during the stay and on the potential risks associated with the circulation of these pathogens after the trip.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02868541
Study type	Observational
Source	Assistance Publique Hopitaux De Marseille
Contact
Status	Completed
Phase
Start date	January 25, 2017
Completion date	September 6, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03943654` - Improving Nighttime Access to Care and Treatment (Part 2)
Completed	`NCT05269290` - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections	Phase 3
Completed	`NCT06385821` - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus	Phase 3
Not yet recruiting	`NCT05902702` - Isotonic Saline for Children With Bronchiolitis	N/A
Not yet recruiting	`NCT04525118` - Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-based Study Platform
Completed	`NCT01431469` - Efficacy and Tolerance of a Follow-On Formula Fed to Children From 12-48 Months of Age in Salvador, Bahia, Brazil	N/A
Completed	`NCT00981513` - Direct and Indirect Benefits of Influenza Vaccination in Schools and Households	Phase 4
Recruiting	`NCT06183229` - Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza	Phase 3
Completed	`NCT03274310` - FluSAFE: Flu SMS Alerts to Freeze Exposure	N/A
Completed	`NCT03736096` - Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients
Completed	`NCT03189537` - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections	Phase 3
Completed	`NCT03028077` - Effects of GS-3K8 and GINst15 on Acute Respiratory Illness	N/A
Enrolling by invitation	`NCT01286285` - Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria	N/A
Completed	`NCT03840135` - Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI	Phase 3
Completed	`NCT01488435` - Efficacy and Tolerance of a Follow-On Formula Fed to Children From 36-48 Months of Age	N/A
Not yet recruiting	`NCT00545961` - Middle Meatal Bacteriology During Acute Respiratory Infection in Children	Phase 4
Completed	`NCT05273619` - Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection	Phase 3
Recruiting	`NCT04415827` - Energy Supply in Athletes and Untrained Persons With Bronchopulmonary Diseases	N/A
Completed	`NCT03459391` - Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers	Phase 1
Withdrawn	`NCT04938323` - Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Assessment of Pharyngeal Carriage of Microorganisms Responsible for Transmissible Acute Respiratory Infections in HAJJ Pilgrims. — EMIRATH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms